Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry

References

• Mease P, Khan M. Axial spondyloarthritis. Amsterdam: Elsevier; 2019.
   Google Scholar
• Zhu W, He X, Cheng K, et al. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019;7(1):22. doi:10.1038/s41413-019-0057-8.
   PubMedGoogle Scholar
• van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–368. doi:10.1002/art.1780270401.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewe R, et al. The development of assessment of SpondyloArthritis International Society Classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–783. doi:10.1136/ard.2009.108233.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31. doi:10.1136/ard.2010.133645.
   PubMed Web of Science ®Google Scholar
• Strand V, Singh JA. Patient burden of axial spondyloarthritis. J Clin Rheumatol. 2017;23(7):383–391. doi:10.1097/RHU.0000000000000589.
   PubMed Web of Science ®Google Scholar
• Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022;18(4):205–216. doi:10.1038/s41584-022-00761-z.
   PubMed Web of Science ®Google Scholar
• Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res. 2012;64(6):905–910. doi:10.1002/acr.21621.
   PubMed Web of Science ®Google Scholar
• Reveille JD, Weisman MH. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States. Am J Med Sci. 2013;345(6):431–436. doi:10.1097/maj.0b013e318294457f.
   PubMed Web of Science ®Google Scholar
• Reveille JD. Epidemiology of spondyloarthritis in North America. Am J Med Sci. 2011;341(4):284–286. doi:10.1097/MAJ.0b013e31820f8c99.
   PubMed Web of Science ®Google Scholar
• Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol. 2018;30(2):137–143. doi:10.1097/BOR.0000000000000475.
   PubMed Web of Science ®Google Scholar
• Dube CE, Lapane KL, Ferrucci KA, et al. Personal experiences with diagnostic delay among axial spondyloarthritis patients: a qualitative study. Rheumatol Ther. 2021;8(2):1015–1030. doi:10.1007/s40744-021-00321-z.
   PubMed Web of Science ®Google Scholar
• Ogdie A, Benjamin Nowell W, Reynolds R, et al. Real-world patient experience on the path to diagnosis of ankylosing spondylitis. Rheumatol Ther. 2019;6(2):255–267. doi:10.1007/s40744-019-0153-7.
   PubMed Web of Science ®Google Scholar
• Walsh JA, Magrey M. Clinical manifestations and diagnosis of axial spondyloarthritis. J Clin Rheumatol. 2021;27(8):e547–e560. doi:10.1097/RHU.0000000000001575.
   PubMed Web of Science ®Google Scholar
• Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res. 2019;71(10):1285–1299. doi:10.1002/acr.24025.
   PubMed Web of Science ®Google Scholar
• Sepriano A, Regel A, van der Heijde D, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3(1):e000396. doi:10.1136/rmdopen-2016-000396.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991. doi:10.1136/annrheumdis-2016-210770.
   PubMed Web of Science ®Google Scholar
• National Guideline Centre (UK). Treat-to-target: rheumatoid arthritis in adults: diagnosis and management: evidence review C. London: National Institute for Health and Care Excellence (NICE); 2018 Jul. (NICE Guideline, No. 100.).
   Google Scholar
• Molto A, López-Medina C, Van den Bosch FE, et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomized TICOSPA trial. Ann Rheum Dis. 2021;80(11):1436–1444. doi:10.1136/annrheumdis-2020-219585.
   PubMed Web of Science ®Google Scholar
• Corrigan-Curay J, Sacks L, Woodcock J. Real-World evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320(9):867–868. doi:10.1001/jama.2018.10136.
   PubMed Web of Science ®Google Scholar
• Beaulieu-Jones BK, Finlayson SG, Yuan W, et al. Examining the use of real-world evidence in the regulatory process. Clin Pharmacol Ther. 2020;107(4):843–852. doi:10.1002/cpt.1658.
   PubMed Web of Science ®Google Scholar
• Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–1774. doi:10.1007/s12325-018-0805-y.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Heijde DV, Karki C, et al. Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US-based Corrona registry. Arthritis Care Res . 2018;70(11):1661–1670. doi:10.1002/acr.23534.
   Web of Science ®Google Scholar
• Kremer JM. The Corrona US registry of rheumatic and autoimmune diseases. Clin Exp Rheumatol. 2016;34(5 Suppl 101):S96–S99.
   PubMed Web of Science ®Google Scholar
• Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58(7):1981–1991. doi:10.1002/art.23606.
   PubMed Web of Science ®Google Scholar
• Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014;73(1):39–47. doi:10.1136/annrheumdis-2013-204231.
   PubMed Web of Science ®Google Scholar
• Lindström U, Olofsson T, Wedrén S, et al. Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice. Arthritis Res Ther. 2019;21(1):128–138. doi:10.1186/s13075-019-1908-9.
   PubMedGoogle Scholar
• Moltó A, Etcheto A, Gossec L, et al. Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers’ effectiveness in axial spondyloarthritis: results of a prospective, multicenter study. Ann Rheum Dis. 2018;77(4):533–540. doi:10.1136/annrheumdis-2017-212378.
   PubMed Web of Science ®Google Scholar
• Maguire S, Fitzgerald G, Gallagher P, et al. Advances in treatment of axial spondyloarthritis are associated with improved patient outcomes: data from the ankylosing spondylitis registry of Ireland (ASRI). Rheumatol Int. 2022;42(5):831–838. doi:10.1007/s00296-021-05067-z.
   PubMed Web of Science ®Google Scholar
• Shim J, Jones G, Pathan EMI, et al. Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis. Ann Rheum Dis. 2018;77(11):1578–1584. doi:10.1136/annrheumdis-2018-213590.
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomized, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705–1713. doi:10.1016/S0140-6736(13)61134-4.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–2548. doi:10.1056/NEJMoa1505066.
   PubMed Web of Science ®Google Scholar
• Karel P, Kivitz A, Dokoupilova R, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285. doi:10.1186/s13075-017-1490-y.
   PubMedGoogle Scholar
• Deodhar A, Poddubnyy D, Pacheco C, The COAST‐W study group, et al. And safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen‐week results from a phase III randomized, double‐blind, placebo‐controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599–611. doi:10.1002/art.40753.
   PubMed Web of Science ®Google Scholar
• Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (Coast-X): a randomized, placebo-controlled trial. Lancet. 2020;395(10217):53–64. doi: 10.1016/S0140-6736(19)32971-X.
   Web of Science ®Google Scholar
• van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (Coast-V): 16-week results of a phase 3 randomized, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441–2451. doi:10.1016/S0140-6736(18)31946-9.
   PubMed Web of Science ®Google Scholar
• Yin Y, Mingjun W, Mengru L, et al. Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Res Ther. 2020;22(1):111. doi:10.1186/s13075-020-02208-w.
   PubMed Web of Science ®Google Scholar
• Brandt J, Listing J, Sieper J, et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63(11):1438–1444. doi:10.1136/ard.2003.016717.
   PubMed Web of Science ®Google Scholar
• Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18–24. doi:10.1136/ard.2008.094870.
   PubMed Web of Science ®Google Scholar
• Machado P, Landewé R, Lie E, et al. Ankylosing spondylitis disease activity score (ASDAS): defining cut- off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47–53. doi:10.1136/ard.2010.138594.
   PubMed Web of Science ®Google Scholar
• Rendas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-x inhibitors. Arthritis Res Ther. 2011;13(1):R25. doi:10.1186/ar3249.
   PubMed Web of Science ®Google Scholar
• Sánchez-Piedra C, Sueiro-Delgado D, García-González J, et al. Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years. Sci Rep. 2021;11(1):15051. doi:10.1038/s41598-021-94504-x.
   PubMed Web of Science ®Google Scholar
• Liew JW, Dubreuil M. Treat to target in axial spondyloarthritis: pros, cons, and future directions. Rheum Dis Clin North Am. 2020;46(2):343–356. doi:10.1016/j.rdc.2020.01.011.
   PubMed Web of Science ®Google Scholar
• Dougados M. Treat to target in axial spondyloarthritis: from its concept to its implementation. J Autoimmun. 2020;110:102398. doi:10.1016/j.jaut.2019.102398.
   PubMed Web of Science ®Google Scholar
• Mease P. Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol. 2017;29(4):304–310. doi:10.1097/BOR.0000000000000388.
   PubMed Web of Science ®Google Scholar
• Macfarlane GJ, Pathan E, Jones GT, et al. Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology. 2020;59(9):2481–2490. doi:10.1093/rheumatology/kez657.
   PubMed Web of Science ®Google Scholar
• Mease P. Emerging immunomodulatory therapies and new treatment paradigms for axial spondyloarthritis. Curr Rheumatol Rep. 2019 Jun 6;21(7):35. doi:10.1007/s11926-019-0830-0.
   PubMed Web of Science ®Google Scholar
• Maguire S, Sengupta R, O'Shea F. The future of axial spondyloarthritis treatment. Rheum Dis Clin North Am. 2020;46(2):357–365. doi:10.1016/j.rdc.2020.01.014.
   PubMed Web of Science ®Google Scholar
• Aletaha D. Precision medicine and management of rheumatoid arthritis. J Autoimmun. 2020;110:102405. doi:10.1016/j.jaut.2020.102405.
   PubMed Web of Science ®Google Scholar